Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04807972
Title Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

pancreatic adenocarcinoma

Therapies

ABBV-181 + ABBV-927 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

ABBV-927 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.